C. Charbonneau

发表

A retrospective study of cholinesterase inhibitors for Alzheimer's disease : the effect of cerebrovascular disease on patient outcomes and the impact of biases on the results

C. Charbonneau, 2011 .

Cost analysis of voriconazole versus liposomal amphotericin B for primary therapy of invasive aspergillosis among patients with haematological disorders in Germany and Spain

C. Solano, C. Charbonneau, J. Stephens, 2014, BMC Pharmacology and Toxicology.

Value of hospital antimicrobial stewardship programs [ASPs]: a systematic review

D. Nathwani, C. Charbonneau, J. Stephens, 2019, Antimicrobial Resistance & Infection Control.

Drug Utilization Review of Cholinesterase Inhibitors in Quebec

M. Dorais, C. Charbonneau, J. LeLorier, 2008, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

Implementing criteria-based early switch/early discharge programmes: a European perspective.

S. Corman, D. Nathwani, C. Charbonneau, 2015, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Treatment of immunocompromised patients with suspected invasive fungal infections: economic analysis of diagnostic-driven versus empirical strategies in Algeria and Egypt

C. Charbonneau, Xin Gao, M. Xue, 2019, Expert review of pharmacoeconomics & outcomes research.

Cost-effectiveness analysis of voriconazole, fluconazole, and amphotericin B for invasive fungal infections following allogeneic hematopoietic stem cell transplantation in Mexico

C. Charbonneau, J. Stephens, E. Rodriguez-Noriega, 2018, ClinicoEconomics and outcomes research : CEOR.

Economic evaluation of sunitinib malate for the first-line treatment of metastatic renal cell carcinoma.

R. Motzer, C. Charbonneau, E. Remák, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Towards a global definition of responsible antibiotic use: results of an international multidisciplinary consensus procedure

I. Okeke, N. Adriaenssens, C. Mcnulty, 2018, The Journal of antimicrobial chemotherapy.

Multicenter, randomized phase II trial of oral CI-1033 for previously treated advanced ovarian cancer.

A. Oza, H. Hirte, E. Kaldjian, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

University of Dundee Value of hospital antimicrobial stewardship programs [ ASPs ]

D. Nathwani, C. Charbonneau, J. Stephens, 2019 .

Economic analysis of ceftaroline fosamil for treating community-acquired pneumonia in Spain

T. Welte, M. Bassetti, A. Torres, 2019, Journal of Medical Economics.

Cost-effectiveness analysis of anidulafungin for the treatment of candidaemia and other forms of invasive candidiasis

G. Auzinger, C. Charbonneau, C. Graham, 2015, BMC Infectious Diseases.

PIN18 - ESTIMATING THE BUDGET AND CLINICAL IMPACT OF INTRODUCING ISAVUCONAZOLE FOR THE TREATMENT OF PATIENTS WITH POSSIBLE INVASIVE ASPERGILLOSIS IN THE UNITED KINGDOM

C. Charbonneau, D. Weidlich, L. Floros, 2018, Value in Health.

Cost-effectiveness analysis of anidulafungin in the treatment of candidaemia

G. Auzinger, C. Charbonneau, C. Graham, 2013, Critical Care.

Cost-effectiveness Comparison of Ceftazidime/Avibactam Versus Meropenem in the Empirical Treatment of Hospital-acquired Pneumonia, Including Ventilator-associated Pneumonia, in Italy.

M. Bassetti, A. Torres, C. Charbonneau, 2020, Clinical therapeutics.

Quality of life (QOL) predicts for progression-free survival (PFS) in patients with metastatic renal cell carcinoma (mRCC) treated with sunitinib compared to interferon-alpha (IFN-{alpha})

R. Motzer, M. Michaelson, D. Cella, 2007 .

Clinical and economic burden of invasive fungal diseases in Europe: focus on pre-emptive and empirical treatment of Aspergillus and Candida species

C. Charbonneau, J. Stephens, R. Barnes, 2013, European Journal of Clinical Microbiology & Infectious Diseases.

Burden and treatment patterns of invasive fungal infections in hospitalized patients in the Middle East: real-world data from Saudi Arabia and Lebanon

S. Corman, F. Farahat, C. Charbonneau, 2017, Infection and drug resistance.

Economic Comparison of an Empirical Versus Diagnostic-Driven Strategy for Treating Invasive Fungal Disease in Immunocompromised Patients.

E. Bow, C. Charbonneau, R. Herbrecht, 2015, Clinical therapeutics.

Comment on ‘Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib’

C. Charbonneau, R. Sandin, 2010, British Journal of Cancer.

R. Motzer, J. Cappelleri, A. Bushmakin, 2007 .

Economic evaluation of azoles as primary prophylaxis for the prevention of invasive fungal infections in Spanish patients undergoing allogeneic haematopoietic stem cell transplant

S. Sorensen, C. Solano, D. Vanness, 2017, Mycoses.

Economic analysis of empiric versus diagnostic-driven strategies for immunocompromised patients with suspected fungal infections in the People’s Republic of China

C. Charbonneau, L. Qin, Yixi Chen, 2016, ClinicoEconomics and outcomes research : CEOR.

The epidemiologic, health‐related quality of life, and economic burden of gastrointestinal stromal tumours

C. Charbonneau, P. Reddy, K. Boci, 2007, Journal of clinical pharmacy and therapeutics.

Antibiotic treatment patterns across Europe in patients with complicated skin and soft-tissue infections due to meticillin-resistant Staphylococcus aureus: a plea for implementation of early switch and early discharge criteria.

D. Nathwani, P. Hájek, C. Charbonneau, 2014, International journal of antimicrobial agents.

Characterizing fatigue associated with sunitinib and its impact on health-related quality of life in patients with metastatic renal cell carcinoma

R. Figlin, Mellar P. Davis, R. Motzer, 2014, Cancer.

Nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus treated with linezolid or vancomycin: A secondary economic analysis of resource use from a Spanish perspective.

J. Rello, C. Charbonneau, J. Chastre, 2016, Medicina intensiva.

Comparative Effectiveness Research/Health Technology Assessment (HTA) Analyzing Overall Survival in Randomized Controlled Trials with Crossover and Implications for Economic Evaluation

M. Drummond, M. Weinstein, B. Jönsson, 2014 .

Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review.

C. Charbonneau, Jim Z. Li, Jeffrey D Miller, 2008, Cancer treatment reviews.

Value of hospital antimicrobial stewardship programs [ASPs]: a systematic review

D. Nathwani, C. Charbonneau, J. Stephens, 2019, Antimicrobial Resistance & Infection Control.

Pathophysiology and burden of infection in patients with diabetes mellitus and peripheral vascular disease: focus on skin and soft-tissue infections.

S. Corman, C. Charbonneau, J. Stephens, 2015, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Cost-effectiveness analysis of combination antifungal therapy with voriconazole and anidulafungin versus voriconazole monotherapy for primary treatment of invasive aspergillosis in Spain

C. Charbonneau, J. Maertens, J. Mensa, 2016, ClinicoEconomics and outcomes research : CEOR.

Ceftaroline Fosamil for the Empiric Treatment of Hospitalized Adults with cSSTI: An Economic Analysis from the Perspective of the Spanish National Health System

Á. Soriano, C. Charbonneau, E. Remák, 2022, ClinicoEconomics and outcomes research : CEOR.

Weight-based antibiotic dosing in a real-world European study of complicated skin and soft-tissue infections due to methicillin-resistant Staphylococcus aureus.

S. Corman, D. Nathwani, C. Charbonneau, 2015, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

The Use and Effectiveness of Ceftazidime–Avibactam in Real-World Clinical Practice: EZTEAM Study

Á. Soriano, M. Bassetti, Marisa Sánchez, 2023, Infectious Diseases and Therapy.

Quality of life predicts progression-free survival in patients with metastatic renal cell carcinoma treated with sunitinib versus interferon alfa.

R. Motzer, M. Michaelson, D. Cella, 2009, Journal of oncology practice.

Modeling the economic impact of linezolid versus vancomycin in confirmed nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus

M. Niederman, D. Nathwani, A. Shorr, 2014, Critical Care.

R. Motzer, R. Motzer, M. Michaelson, 2010, British Journal of Cancer.

Estimating the Value of New Antimicrobials in the Context of Antimicrobial Resistance: Development and Application of a Dynamic Disease Transmission Model

J. Otter, N. Hawkins, M. Lumley, 2020, PharmacoEconomics.

Baseline quality of life as a prognostic survival tool in patients receiving sunitinib for metastatic renal cell carcinoma

R. Motzer, M. Michaelson, D. Cella, 2012, British Journal of Cancer.

Quality of life in patients with metastatic renal cell carcinoma treated with sunitinib or interferon alfa: results from a phase III randomized trial.

R. Motzer, D. Cella, J. Cappelleri, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comparison of vancomycin and linezolid in patients with peripheral vascular disease and/or diabetes in an observational European study of complicated skin and soft-tissue infections due to methicillin-resistant Staphylococcus aureus.

S. Corman, D. Nathwani, C. Charbonneau, 2015, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Pharmacoeconomic analysis of antifungal therapy for primary treatment of invasive candidiasis caused by Candida albicans and non-albicans Candida species

Yee-Chun Chen, C. Charbonneau, H. Ou, 2017, BMC Infectious Diseases.

Assessment of progression-free survival as a surrogate end-point for overall survival in patients with metastatic renal cell carcinoma.

R. Figlin, R. Motzer, M. Michaelson, 2011, European journal of cancer.

Economic evaluation of new targeted therapies for the first‐line treatment of patients with metastatic renal cell carcinoma

R. Figlin, U. Harmenberg, Á. Benedict, 2011, BJU international.

Infection and Drug Resistance Dovepress an Economic Model to Compare Linezolid and Vancomycin for the Treatment of Confirmed Methicillin-resistant Staphylococcus Aureus Nosocomial Pneumonia in Germany

C. Charbonneau, J. Stephens, B. Weber, 2022 .

A retrospective study of cholinesterase inhibitors for Alzheimer's disease: cerebrovascular disease as a predictor of patient outcomes

M. Dorais, C. Charbonneau, J. LeLorier, 2008 .

Using the Rasch model to validate and enhance the interpretation of the Functional Assessment of Cancer Therapy-Kidney Symptom Index--Disease-Related Symptoms scale.

R. Motzer, D. Cella, J. Cappelleri, 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.